Document is current
Any future updates will be listed below
-
Authors
Alexandrov, Anne W.
Ryschon, Anne M.
Choi, Huimahn A.
Badjatia, Neeraj
Cusack, Thomas J.
Alexandrov, Andrei V.
Mayer, Stephan A.
Pietzsch, Jan B. https://orcid.org/0000-0002-5078-1939
-
Funding
Funding for this research was provided by:
Phagenesis Inc.
- License Information
-
More Information
Article History
Received: 16 January 2026
Accepted: 18 March 2026
First Online: 13 April 2026
Declarations
:
: Anne M. Ryschon and Jan B. Pietzsch report consulting fees through their employer, Wing Tech Inc. from Phagenesis Inc. and Lungpacer USA Inc.; Huimahn A. Choi reports consulting for Grace Therapeutics and Aurenar; Stephan A. Mayer reports consulting fees from Phagenesis Inc.; Anne W. Alexandrov, Neeraj Badjatia, Thomas J. Cusack, and Andrei V. Alexandrov do not report any conflicts.
: This study used de-identified administrative data from CMS MEDPAR files. As all data were de-identified and available for research use under a data use agreement, this study did not involve human subjects as defined by federal regulations (45 CFR 46.102). Accordingly, institutional review board (IRB) approval and informed consent were not required.
